Bioventure Leads Series A+ Round In Antiviral Drugs Maker Ark Biosciences

For Digital Subscribers Only

Chinese medical and pharmaceutical-focused venture fund Bioventure Investment Management Ltd. has led an undisclosed series A+ round in Ark Biosciences, a Shanghai-based drug developer targeting respiratory viruses, influenza and Hepatitis B.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in


RELATED NEWS



LEAVE A REPLY